• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sab Biotherapeutics Inc (NQ: SABS )

    2.700 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 2.700
    Bid (Size) 1.760 (1)
    Ask (Size) 4.310 (1)
    Prev. Close 2.700
    Today's Range 2.700 - 2.700
    52wk Range 2.160 - 10.50
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -61.43%
    -61.43%
    1 Month
    -1.82%
    -1.82%
    3 Month
    -16.92%
    -16.92%
    6 Month
    -50.00%
    -50.00%
    1 Year
    -54.77%
    -54.77%

    More News

    Read More
    SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SABS Stock Earnings: SAB Biotherapeutics Beats EPS for Q2 2024
    Via InvestorPlace
    SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    SAB BIO Appoints Lucy To as Chief Financial Officer
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAb Biotherapeutics Rebrands as SAB BIO
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Departure of Chief Financial Officer
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Provides SAB-142 Trial Update
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at INNODIA Annual Meeting
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    SAB Biotherapeutics Announces Executive Leadership Change
    From SAB Biotherapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.